科研之友
微信
新浪微博
Facebook
分享链接
摘要
Objective: Discordant efficacy and safety of capecitabine-based chemotherapy versus capecitabine-free chemotherapy were reported by previous trials. Our meta-analysis aimed to determine the efficacy and safety of capecitabine-based chemotherapy verse capecitabine-free chemotherapy in patients with metastatic breast cancer. Methods: Literatures were searched in Pubmed, Medline and Embase from January 1990 to January 2015 in this study. Studies of parallel group design comparing capecitabine-based chemotherapy and capecitabine-free chemotherapy for metastatic breast cancer were screened. After independent review of 732 citations by 2 authors, ten studies were identified as meeting the inclusion criteria. Results: Our study showed that capecitabine-based chemotherapy had a similar clinical response, partial response, overall response and progression free survival with capecitabine-free chemotherapy. However, patients treated with capecitabine-based chemotherapy had a better overall survival than patients treated with capecitabine-free chemotherapy (OR=0.8, 95% CI: 0.68 to 0.95). Neutropenia (OR=1.22, 95% CI: 1.05-1.41) and leukocytopenia (OR=1.36, 95% CI: 1.13-1.63) occurred less in capecitabine-based chemotherapy group. Significantly more diarrhea (OR=0.46, 95% CI: 0.32-0.65), nausea (OR=0.47, 95% CI: 0.24-0.89) and hand-foot syndrome (OR=0.07, 95% CI: 0.04-0.17) occurred in capecitabine-based chemotherapy group than in capecitabine-free chemotherapy group. Conclusion: Our study indicated that capecitabine-based chemotherapy is as effective as capecitabine-free chemotherapy in patients with metastatic breast cancer with better overall survival and acceptable toxicity profiles.
